Literature DB >> 21541793

Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.

Andreas Reiff1, Bracha Shaham, Kenneth I Weinberg, Gay M Crooks, Robertson Parkman.   

Abstract

Autologous hematopoietic stem cell transplantation (HSCT) has been used for the treatment of both adult and pediatric autoimmune diseases. However, HSCT has significant side effects (neutropenia, thrombocytopenia, infertility, cardiotoxicity) and costs (HSC collection/harvesting, blood product support). In an attempt to avoid the toxicities and costs associated with HSCT, we investigated whether immune ablation similar to that achieved following myeloablative HSCT could be achieved by the intensive administration of an anti-CD52 antibody (Campath-1H antibody). The first patient treated with the treatment regime, who had refractory juvenile polymyositis, achieved immune ablation (the elimination of pre-therapy antigen-specific T lymphocyte immunity) and has had stable clinical improvement for more than 6 years.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21541793     DOI: 10.1007/s10875-011-9533-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  21 in total

1.  Antigen-specific T-lymphocyte function after cord blood transplantation.

Authors:  Geoff Cohen; Shelly L Carter; Kenneth I Weinberg; Bernadette Masinsin; Eva Guinan; Joanne Kurtzberg; John E Wagner; Nancy A Kernan; Robertson Parkman
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

2.  Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow.

Authors:  H D Ottinger; D W Beelen; B Scheulen; U W Schaefer; H Grosse-Wilde
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

3.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Authors:  Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study.

Authors:  A Fassas; A Anagnostopoulos; A Kazis; K Kapinas; I Sakellari; V Kimiskidis; A Tsompanakou
Journal:  Bone Marrow Transplant       Date:  1997-10       Impact factor: 5.483

5.  Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.

Authors:  Oana I Craciunescu; Beverly A Steffey; Chris R Kelsey; Nicole A Larrier; Cathy J Paarz-Largay; Robert G Prosnitz; Nelson Chao; John Chute; Cristina Gasparetto; Mitchell Horwitz; Gwynn Long; David Rizzieri; Keith M Sullivan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

6.  Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

Authors:  Dominique Farge; Myriam Labopin; Alan Tyndall; Athanasios Fassas; Gian Luigi Mancardi; Jaap Van Laar; Jian Ouyang; Tomas Kozak; John Moore; Ina Kötter; Virginie Chesnel; Alberto Marmont; Alois Gratwohl; Riccardo Saccardi
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

7.  Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Authors:  C L Hirst; A Pace; T P Pickersgill; R Jones; B N McLean; J P Zajicek; N J Scolding; N P Robertson
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

8.  Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.

Authors:  G Hale; M J Zhang; D Bunjes; H G Prentice; D Spence; M M Horowitz; A J Barrett; H Waldmann
Journal:  Blood       Date:  1998-12-15       Impact factor: 22.113

Review 9.  Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States.

Authors:  Keith M Sullivan; Paolo Muraro; Alan Tyndall
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-04       Impact factor: 5.742

10.  The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.

Authors:  Ami J Shah; Neena Kapoor; Gay M Crooks; Kenneth I Weinberg; Hisham Abdel Azim; Renna Killen; Lily Kuo; Teresa Rushing; Donald B Kohn; Robertson Parkman
Journal:  Biol Blood Marrow Transplant       Date:  2007-03-23       Impact factor: 5.742

View more
  5 in total

1.  The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Authors:  Pooja Khandelwal; Julia Lawrence; Alexandra H Filipovich; Stella M Davies; Jacob J Bleesing; Michael B Jordan; Parinda Mehta; Sonata Jodele; Michael S Grimley; Ashish Kumar; Kasiani Myers; Rebecca A Marsh
Journal:  Pediatr Transplant       Date:  2013-10-30

Review 2.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 3.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

4.  A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Pooja Khandelwal; Chie Emoto; Tsuyoshi Fukuda; Alexander A Vinks; Lisa Neumeier; Christopher E Dandoy; Javier El-Bietar; Sharat Chandra; Stella M Davies; Jacob J Bleesing; Michael B Jordan; Parinda A Mehta; Sonata Jodele; Michael S Grimley; Ashish Kumar; Kasiani C Myers; Rebecca A Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-21       Impact factor: 5.742

Review 5.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.